Lazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer

  • Post author:
  • Post category:

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 6 March 2025, approved lazertinib (brand name Lazcluze) for adults with non-small cell lung cancer that has spread to other…

Continue ReadingLazertinib approved for use in combination with amivantamab for the treatment of adults with non-small cell lung cancer

The EBA consults on new rules related to the anti-money laundering and countering the financing of terrorism package

  • Post author:
  • Post category:

The European Banking Authority (EBA) launched today a public consultation on four draft Regulatory Technical Standards (RTS) that will be part of the EBA’s response to the European Commission’s Call…

Continue ReadingThe EBA consults on new rules related to the anti-money laundering and countering the financing of terrorism package